[1] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255]. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
[2] Vrablík, Michal, et al.. "Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019." Cor Vasa 62.2 (2020): 185-97. Print.
[3] Ošťádal, Petr, et al.. "Stručný souhrn doporučení pro dlouhodobou péči o nemocné po infarktu myokardu 2022." Cor Vasa 64.Suppl.1 (2022): 7-28. Print.
[4] Aboyans, Victor et al. “2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases(ESVS).” European heart journal vol. 39,9 (2018): 763-816. doi:10.1093/eurheartj/ehx095
[5] Sacco, Ralph L et al. “Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack.” Stroke vol. 37,2 (2006): 577-617. doi:10.1161/01.STR.0000199147.30016.74
[6] Cholesterol Treatment Trialists’ (CTT) Collaboration et al. “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.” Lancet (London, England) vol. 376,9753 (2010): 1670-81. doi:10.1016/S0140-6736(10)61350-5
CZ2208261634/08/2022